Shahneen Sandhu
Royal Women's Hospital(AU)University of Connecticut(US)The University of Melbourne(AU)University of Melbourne(AU)Peter MacCallum Cancer Centre(AU)Royal Hobart Hospital(AU)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Radiopharmaceutical Chemistry and Applications, PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics
Most-Cited Works
- → Olaparib for Metastatic Castration-Resistant Prostate Cancer(2020)2,172 cited
- → DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer(2015)2,165 cited
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer(2019)1,551 cited
- → [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study(2018)1,115 cited
- → [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial(2021)1,014 cited